Primary Hyperoxaluria Type 1 (PH1) is a rare genetic disorder that causes the liver to produce excessive oxalate, a substance that can crystallize and damage the kidneys and other organs. Patients often suffer from recurrent kidney stones, kidney failure, and other serious complications. Historically, treatment options were limited, focusing mainly on symptom management rather than addressing the underlying cause.
Recent medical advancements have brought new hope to patients in the UAE, offering effective therapies that target the root cause of PH1 and improve quality of life.
Understanding Primary Hyperoxaluria Type 1
PH1 is caused by mutations in the AGXT gene, which leads to a deficiency in the enzyme alanine-glyoxylate aminotransferase. This enzyme deficiency results in the accumulation of oxalate in the body. Over time, oxalate crystals can deposit in the kidneys, liver, bones, and other organs, causing significant damage.
Symptoms usually appear in childhood and include frequent kidney stones, blood in the urine, abdominal pain, urinary tract infections, and eventually, kidney failure. Early detection is critical to managing the disease and preventing irreversible damage.
Traditional Treatment Approaches
For decades, treatments for PH1 were mainly supportive and focused on reducing oxalate levels and preventing complications. Some of the commonly used approaches included:
- High fluid intake: Patients were encouraged to drink plenty of water to dilute urine and reduce the risk of kidney stone formation.
- Dietary changes: Avoiding oxalate-rich foods and increasing calcium intake could help limit oxalate accumulation.
- Vitamin B6 (Pyridoxine): Some patients respond to vitamin B6, which can reduce oxalate production in the liver.
- Dialysis or kidney transplantation: In cases of advanced kidney failure, these interventions were necessary to maintain kidney function.
While these measures helped manage symptoms, they did not cure the disease or address the underlying genetic cause.
Breakthrough Therapies
Recent scientific breakthroughs have introduced targeted therapies that aim to reduce oxalate production and improve outcomes for PH1 patients. These treatments have transformed the disease landscape, especially in countries like the UAE.
Lumasiran (Oxlumo)
Lumasiran is an RNA interference (RNAi) therapy that targets the liver enzyme glycolate oxidase, which plays a key role in oxalate production. By inhibiting this enzyme, lumasiran effectively reduces oxalate levels in the body. Clinical studies have shown significant decreases in both urinary and plasma oxalate levels, lowering the risk of kidney stones and slowing kidney damage.
Lumasiran is administered through a simple injection, and patients typically receive treatment every few months. It has been approved in several countries, including the UAE, and represents a major advancement in PH1 management.
Nedosiran (Rivfloza)
Nedosiran is another RNAi-based therapy designed to target lactate dehydrogenase A (LDHA), an enzyme involved in oxalate production. By reducing the activity of LDHA, nedosiran helps decrease oxalate levels in the body. Clinical trials have demonstrated promising results, including improved kidney function and a reduction in urinary oxalate excretion.
Nedosiran offers an additional treatment option for patients, particularly for those who may not respond adequately to other therapies.
Gene Editing and Future Therapies
Beyond RNAi therapies, gene editing offers the potential for a one-time, curative treatment for PH1. Researchers are exploring innovative techniques to correct the genetic mutation responsible for the disease.
ABO-101
ABO-101 is an experimental therapy that targets the HAO1 gene, which contributes to oxalate production. Preclinical studies have shown that this therapy can significantly reduce oxalate levels and preserve liver function. Ongoing clinical trials are evaluating the safety and effectiveness of ABO-101 in human patients.
YOLT-203
YOLT-203 is a CRISPR/Cas9-based therapy that directly edits the HAO1 gene in liver cells. Early clinical results indicate significant reductions in oxalate production and improvements in kidney health. These gene-editing approaches could offer long-term solutions for patients who currently require lifelong treatment.
Implementation in the UAE
The UAE has been proactive in adopting advanced medical treatments for rare diseases like PH1. Recently, healthcare authorities and specialist organizations announced the availability of new therapies, including lumasiran, for patients in the region.
Specialized medical centers in the UAE are now equipped to provide comprehensive care, including genetic testing, counseling, and treatment administration. Regulatory authorities have streamlined approval processes for rare disease therapies, ensuring that patients can access new treatments in a timely manner.
Public awareness campaigns and collaboration with patient advocacy groups are also helping families understand the disease, recognize symptoms early, and seek appropriate care. These initiatives are vital for improving outcomes and ensuring that patients benefit from the latest medical advancements.
Challenges and Considerations
Despite these promising developments, several challenges remain in managing PH1 in the UAE and worldwide:
- Access to treatment: Ensuring all patients have access to advanced therapies, regardless of geographic location or socioeconomic status.
- Early diagnosis: Raising awareness among healthcare providers to recognize the disease early and initiate timely treatment.
- Long-term monitoring: Collecting data on the safety and effectiveness of new therapies over time to guide future treatment decisions.
Addressing these challenges will require coordinated efforts among healthcare professionals, government authorities, and patient advocacy organizations.
Conclusion
The availability of advanced therapies for Primary Hyperoxaluria Type 1 in the UAE offers renewed hope for patients and families affected by this rare genetic disorder. Treatments like lumasiran and nedosiran, along with emerging gene-editing therapies, have transformed the outlook for PH1, moving from symptom management to targeted treatment.
With continued research, public awareness, and access to innovative therapies, patients in the UAE can look forward to improved kidney health, reduced complications, and a better quality of life. The advancements in PH1 treatment demonstrate the power of modern medicine and highlight the UAE’s commitment to healthcare innovation.
Do follow UAE Stories on Instagram
Read Next – UAE Non-Oil Private Sector Sees Strongest Growth in Seven Months
